FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and BPC 157 for Foot Pain Houston Podiatrist Explains The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions FDA Peptide Update: Category 2 Removals Explained